Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The ENST00000231790.8(MLH1):c.1668-19A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.414 in 1,544,504 control chromosomes in the GnomAD database, including 137,265 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★). There are indicators that this mutation may affect the branch point..
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
This place is a probable branch point but likely benign (scored 1 / 10). Computational evidence support a benign effect (BayesDel_noAF=-0.84).
BP6
Variant 3-37042249-A-G is Benign according to our data. Variant chr3-37042249-A-G is described in ClinVar as [Benign]. Clinvar id is 36542.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr3-37042249-A-G is described in Lovd as [Benign]. Variant chr3-37042249-A-G is described in Lovd as [Pathogenic]. Variant chr3-37042249-A-G is described in Lovd as [Likely_benign].
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.447 is higher than 0.05.
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
-
- -
Benign, no assertion criteria provided
clinical testing
Clinical Genetics, Academic Medical Center
-
- -
Benign, no assertion criteria provided
clinical testing
Genome Diagnostics Laboratory, University Medical Center Utrecht
-
- -
Benign, no assertion criteria provided
clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
-
- -
Benign, no assertion criteria provided
clinical testing
Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute
-
- -
Benign, no assertion criteria provided
clinical testing
Mayo Clinic Laboratories, Mayo Clinic
-
- -
Benign, criteria provided, single submitter
clinical testing
PreventionGenetics, part of Exact Sciences
-
- -
Benign, criteria provided, single submitter
clinical testing
Eurofins Ntd Llc (ga)
Jun 24, 2014
- -
not provided Uncertain:1Benign:3
Uncertain significance, no assertion criteria provided
clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System
-
- -
Benign, criteria provided, single submitter
not provided
Breakthrough Genomics, Breakthrough Genomics
-
- -
Benign, criteria provided, single submitter
clinical testing
GeneDx
Mar 03, 2015
- -
Benign, criteria provided, single submitter
clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Nov 30, 2023
- -
Colorectal cancer, hereditary nonpolyposis, type 2 Benign:2
Benign, criteria provided, single submitter
clinical testing
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Jul 07, 2023
- -
Benign, no assertion criteria provided
clinical testing
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
-
- -
Lynch syndrome Benign:2
Benign, criteria provided, single submitter
clinical testing;curation
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Aug 18, 2011
- -
Benign, reviewed by expert panel
research
International Society for Gastrointestinal Hereditary Tumours (InSiGHT)
Sep 05, 2013
MAF >1% -
Hereditary cancer-predisposing syndrome Benign:2
Benign, criteria provided, single submitter
clinical testing
Color Diagnostics, LLC DBA Color Health
Mar 31, 2015
- -
Benign, criteria provided, single submitter
clinical testing
Ambry Genetics
Nov 18, 2014
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -